title: [Non-resecable gastric cancers at the department of general surgery at CHU Gabriel TOURE Bamako].
abstract: Our objectives were to determine the frequency of non-resecable gastric cancers, to analyse its clinical, and therapeutic aspects, and to assess patients follow-up.
  
  
  
  Our retrospective study has been from 1st January 2008 to 31st December 2009. It included all patients operated or not having non-resecable gastric cancers at general surgery at CHU Gabriel TOURE
  
  
  
  We have recorded 305 cases of advanced gastric cancers, accounting for 71.4% of gastric cancers (n=425), 47.8% of digestive cancers (n=766) and 2.2% of hospitalisations. The sex ratio was 1.6 in men favour; the average age was 57 } 12 with extremes of 25 and 90. The average evolution delay was 15.5 months with extremes of 5 and 7, and standard deviation 19.2. 14 patients have been admitted in an emergency context. (8 cases of gastric perforation related peritonitis, 6 cases d’haematemesis). The main found signs were: epigastric tumours 187 (61.3%) cases, lower limbs oedema 105 (34.4%) cases, ascitis 105(34.4%) cases, hepatomegaly 68(22.3%), lymphadenopathy ≪ ganglions de Troisier ≫21(7%), ≪ ecailles de Brumer ≫ (= Brumer’s scales) from rectal touch 17(6%) cases More than half of patients have been classified ASA 4.105(34.4%) ASA 5, and 74(24.2%) ASA . The tumour location was antrum in 260(85.2%) cases Cardiac orifice in 17(5.5%) cases, fundus i n 11(3.6%), the gastric linitis in 17(5,5%) cases. The imaging has found the ascitis in 119(39%) cases, the hepatic metastases in 54(17.7%) cases, pulmonary in 36(19%) cases, pancreatic 5(1.6%) cases, splenic in 4(1.3%), and ovarian in 3(1%) cases 105(34.4%) patients had no surgery, 4(1.3%) had chemotherapy, and 200(65 %) had surgery. The mortality rate was at 16.5% and the one year survival at 15.5%.
authors.affiliation: Departement de chirurgie, CHU Gabriel Toure BP 267 Bamako, Mali. btdembele@gmail.com
authors.forename: B T
authors.initials: BT
authors.lastname: Dembélé
authors.forename: A
authors.initials: A
authors.lastname: Togo
authors.forename: L
authors.initials: L
authors.lastname: Kanté
authors.forename: A
authors.initials: A
authors.lastname: Traoré
authors.forename: I
authors.initials: I
authors.lastname: Diakité
authors.lastname: Tounkara
authors.forename: Y
authors.initials: Y
authors.lastname: Coulibaly
authors.forename: B
authors.initials: B
authors.lastname: Samaké
authors.forename: M
authors.initials: M
authors.lastname: Keita
authors.forename: G
authors.initials: G
authors.lastname: Diallo
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology / Q000556:secondary / Q000601:surgery; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D057210:Delayed Diagnosis; D013505:Digestive System Surgical Procedures / Q000706:statistics & numerical data; D005260:Female; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008302:Mali / Q000453:epidemiology; D008875:Middle Aged; D010166:Palliative Care; D015995:Prevalence; D012189:Retrospective Studies; D017678:Sex Distribution; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery; D013503:Surgery Department, Hospital / Q000706:statistics & numerical data; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents